J
Jean P. Hubble
Researcher at Ohio State University
Publications - 62
Citations - 7153
Jean P. Hubble is an academic researcher from Ohio State University. The author has contributed to research in topics: Essential tremor & Levodopa. The author has an hindex of 38, co-authored 62 publications receiving 6868 citations. Previous affiliations of Jean P. Hubble include Novartis.
Papers
More filters
Journal ArticleDOI
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Robert G. Holloway,Ira Shoulson,Stanley Fahn,Karl Kieburtz,Anthony E. Lang,Kenneth Marek,Michael P. McDermott,John Seibyl,William J. Weiner,Bruno Musch,Cornelia Kamp,Mickie Welsh,Aileen Shinaman,Rajesh Pahwa,Lynn Barclay,Jean P. Hubble,Peter A. LeWitt,Janis M. Miyasaki,Oksana Suchowersky,Mark Stacy,David S. Russell,Blair Ford,John P. Hammerstad,David E. Riley,David G. Standaert,Frederick Wooten,Stewart A. Factor,Joseph Jankovic,Farah Atassi,Roger Kurlan,Michel Panisset,Ali H. Rajput,Robert L. Rodnitzky,Cliff Shults,Giselle Petsinger,Cheryl Waters,Ronald F. Pfeiffer,Kevin M. Biglan,Leona Borchert,Amy Montgomery,Laura Sutherland,Carolyn Weeks,Maryan DeAngelis,Elspeth Sime,Susan Wood,Carol Pantella,Mary Harrigan,Barbara Fussell,Sandra Dillon,Barbara Alexander-Brown,Pamela Rainey,Marsha Tennis,Elke Rost-Ruffner,Diane Brown,Sharon Evans,Debra Berry,Jean Hall,Theresa Shirley,Judith Dobson,Deborah Fontaine,Brenda Pfeiffer,Alicia Brocht,Susan E. Bennett,Susan Daigneault,Karen Hodgeman,Carolynn O'Connell,Tori Ross,Karen Richard,Arthur Watts +68 more
TL;DR: Initial treatment with pramipexole resulted in lower incidences of freezing, somnolence, and edema and provided for better symptomatic control, as measured by the Unified Parkinson's Disease Rating Scale, compared with initial treatment with levodopa, which resulted in similar quality of life.
Journal ArticleDOI
A controlled trial of rasagiline in early Parkinson disease: The tempo study
Andrew Siderowf,Matthew B. Stern,Ira Shoulson,Karl Kieburtz,David Oakes,Denni Day,Aileen Shinaman,Sandra Plumb,Stanley Fahn,Karen Blindauer,Mark F. Lew,Howard I. Hurtig,Mary Lloyd,Robert A. Hauser,Lisa Gauger,Lawrence I. Golbe,Joanne Wojcieszek,Joann Belden,Andrew Feigin,Mary Lou Klimek,Barbara Shannon,William G. Ondo,Christine Hunter,Vincent Calabrese,Paul Atchison,Cathy W. Allen,Frederick J. Marshall,Debra Berry,Irenita Gardiner,Janis M. Miyasaki,Luisa Del Rizzo,Tilak Mendis,Neila Mendis,Peggy Gray,Jean P. Hubble,Karen Betcher,Rajesh Pahwa,Eric Molho,Diane Brown,Lisa M. Shulman,Ali H. Rajput,Marianne Ewanishin,Mark Stacy,Kelli Williamson,John M. Bertoni,Carolyn Peterson,Paul J. Tuite,Brenda Ebbitt,Kathleen M. Shannon,Jean A. Jaglin,Caroline M. Tanner,Kenneth Marek,Karen Stavris,Michael J. Aminoff,Mariann DiMinno,Glenna A. Dowling,Un Jung Kang,Judy Richman,Kapil D. Sethi,W.R. Wayne Martin,Pamela King,Germaine McInnes,Charles H. Adler,Peter A. LeWitt,Maryan DeAngelis,Myrna Schear,Mark Forrest Gordon,Roberta Winnick,Robert G. Feldman,Cathi A. Thomas,Kelly M. Conn,Alicia Brocht,Chris Chadwick,Jeannette Connolly,Susan Daigneault,Shirley Eberly,Janice Bausch,Lee Josephson,Rosemary Oliva,Steven R. Schwid,Anthony E. Lang,Christopher Cox,Carrie Irvine,John G. Nutt,William B. White,Sheila Oren,Ruth Levy,Eli Eyal,David Ladkani,Wayne Houck +89 more
TL;DR: Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Journal ArticleDOI
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
Joelle M. van der Walt,Kristin K. Nicodemus,Eden R. Martin,William K. Scott,Martha Nance,Ray L. Watts,Jean P. Hubble,Jonathan L. Haines,William C. Koller,Kelly E. Lyons,Rajesh Pahwa,Matthew B. Stern,Amy Colcher,Bradley C. Hiner,Joseph Jankovic,William G. Ondo,Fred H. Allen,Christopher G. Goetz,Gary W. Small,Frank L. Mastaglia,Jeffrey M. Stajich,Adam C. McLaurin,Lefkos T. Middleton,Burton L. Scott,Donald E. Schmechel,Margaret A. Pericak-Vance,Jeffery M. Vance +26 more
TL;DR: The results suggest that ND3 is an important factor in PD susceptibility among white individuals and could help explain the role of complex I in PD expression.
Journal ArticleDOI
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
William C. Koller,Rajesh Pahwa,Karen Busenbark,Jean P. Hubble,Steve Wilkinson,Anthony E. Lang,Paul J. Tuite,Elspeth Sime,Lazano A,Robert A. Hauser,Teresita Malapira,Donald A. Smith,Daniel Tarsy,Miyawaki E,Thorkild Norregaard,Kormos T,C. W. Olanow +16 more
TL;DR: Chronic high‐frequency stimulation of the ventral intermedius nucleus of the thalamus is safe and highly effective in ameliorating essential and parkinsonian tremor and measures of function were significantly improved in patients with essential tremor.
Journal ArticleDOI
Long-term evaluation of deep brain stimulation of the thalamus.
Rajesh Pahwa,Kelly E. Lyons,Steven B. Wilkinson,Richard K. Simpson,William G. Ondo,Daniel Tarsy,Thorkild Norregaard,Jean P. Hubble,Donald A. Smith,Robert A. Hauser,Joseph Jankovic +10 more
TL;DR: Thalamic stimulation is safe and effective for the long-term management of essential and Parkinsonian tremors and Bilateral stimulation can cause dysarthria and incoordination and should be used cautiously.